Samsung Biologics has launched a bid to acquire PolyPeptide, a contract development and manufacturing organization focused on peptides. The offer was made public on July 24, 2026. This move would expand Samsung Biologics' capabilities into the peptide manufacturing space.
Samsung Biologics has initiated a bid to acquire PolyPeptide, a contract development and manufacturing organization that specializes in peptide production. The proposal was made public on July 24, 2026. Samsung Biologics is already a major player in the contract manufacturing of biologic drugs, and this acquisition would add peptide manufacturing to its portfolio.
PolyPeptide is a CDMO focused exclusively on peptides. The company provides development and manufacturing services for peptide-based therapeutics, an area of growing interest in the pharmaceutical industry. Peptides are used in treatments for a variety of conditions including diabetes, cancer, and metabolic disorders.
The bid represents a strategic move by Samsung Biologics to diversify its service offerings. By acquiring PolyPeptide, Samsung would gain expertise in peptide chemistry and manufacturing capabilities. The deal would also provide Samsung with access to PolyPeptide's existing customer base and regulatory experience.
The peptide CDMO market has seen increasing demand as more peptide drugs receive regulatory approval. PolyPeptide is one of the few pure-play peptide CDMOs globally, making it an attractive target. Samsung Biologics already operates large-scale mammalian cell culture facilities and adding peptide capabilities would complement its existing services.
At this time, Samsung Biologics has not released specific financial terms of the bid. The acquisition is subject to regulatory approvals and other customary closing conditions. Further details are expected to emerge as the process moves forward.
If completed, the acquisition would strengthen Samsung Biologics' position in the contract manufacturing market. It would also give the company a foothold in the rapidly growing peptide therapeutics space. PolyPeptide's facilities and expertise would be integrated into Samsung Biologics' global operations.
Samsung Biologics is a contract development and manufacturing organization headquartered in South Korea. It provides manufacturing services for biologics including monoclonal antibodies and other protein therapeutics. PolyPeptide, based in Switzerland, has manufacturing sites in Europe and the United States and has been a dedicated peptide CDMO for decades.
Related reading: Peptide and Oligonucleotide CDMO Market to Hit USD 11.42 Billion by 2035, Samsung Biologics to Acquire PolyPeptide for $1.8 Billion, Samsung Biologics acquires PolyPeptide for $1.8 billion, Samsung Biologics Acquires Swiss CDMO for $1.8 Billion to Enter Obesity Drug Market.